Drug Patents owned by Eagle Pharms

1. List of Argatroban In Sodium Chloride drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7589106 EAGLE PHARMS Alcohol free formulation of argatroban
Sep, 2027

(4 years from now)

US7687516 EAGLE PHARMS Alcohol free formulation of argatroban
Sep, 2027

(4 years from now)

Drugs and Companies using ARGATROBAN ingredient

Market Authorisation Date: 29 June, 2011

Treatment: Method of treating thrombosis; Method of treating an argatroban treatable condition

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of ARGATROBAN IN SODIUM CHLORIDE before it's patent expiration?
More Information on Dosage

2. List of Belrapzo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 15 May, 2018

Treatment: For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BELRAPZO before it's patent expiration?
More Information on Dosage

3. List of Bendeka drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(7 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(8 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(10 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(10 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BENDEKA before it's patent expiration?
More Information on Dosage

4. List of Pemfexy drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9604990 EAGLE PHARMS Crystalline forms of pemetrexed diacid and manufacturing processes therefor
Oct, 2035

(12 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7772209 EAGLE PHARMS Antifolate combination therapies
May, 2022

(8 months ago)

Drugs and Companies using PEMETREXED ingredient

Market Authorisation Date: 08 February, 2020

Treatment: Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with mesothelioma; Use of pemetrexed with prior and/or repeated vitamin b12 and folic acid administration in patients with non-squamous non-small cell lung cancer

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

5. List of Ryanodex drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9884044 EAGLE PHARMS Treatment using dantrolene
Jun, 2022

(7 months ago)

US8604072 EAGLE PHARMS Treatment using dantrolene
Jul, 2022

(6 months ago)

US8110225 EAGLE PHARMS Treatment using dantrolene
Dec, 2022

(a month ago)

US8685460 EAGLE PHARMS Treatment using dantrolene
Feb, 2023

(14 days from now)

US7758890 EAGLE PHARMS Treatment using dantrolene
Jun, 2025

(2 years from now)

Drugs and Companies using DANTROLENE SODIUM ingredient

Market Authorisation Date: 22 July, 2014

Treatment: For use in the treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.

Dosage: FOR SUSPENSION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic